The patent covering GroPep's drug for the treatment of recurrent miscarriage provides the company with a European market patent exclusivity until at least 2018. GroPep already has two US patents covering the active ingredient of the drug until 2020.

According to the American College of Obstetricians and Gynecologists, at least 50 percent of recurrent miscarriages have no apparent explanation and there is no cure. The size of the market, the lack of competition and the strong patent position held by GroPep, means that the drug has the potential to participate in a market worth up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX: GRO) today announced that European Patent No. 1028743, covering a method of treating recurrent miscarriage and preeclampsia using GroPep's infertility drug product - PV903, has been granted.

This patent grant is a major product development milestone as it provides the Company with a European market patent exclusivity until at least 2018. The European patent compliments two granted US patents licensed to GroPep by OSI Pharmaceuticals that cover the active ingredient of PV903 and method of manufacture until at least 2020. The combination provides GroPep with patent protection in the world's most valuable markets. The Company is also prosecuting additional patent applications to further extend the patent protection around PV903.

GroPep's Chief Executive Officer, Mr Bob Finder, said that the Company is developing PV903 as a potential treatment for recurrent miscarriage, a traumatic infertility condition with an estimated market potential of over US$750 million per year. There are currently no drugs approved for the treatment of recurrent miscarriage.

The European patent is owned by the Univers
'"/>

Contact: Tony Mitchell
61-88-354-7700
Research Australia
26-Jul-2006